[Effect of COVID-19 pandemics in treatment of cervical cancer: pre/post study].

Pub Date : 2024-01-01
Silvina Arrossi, Fernando Binder, Carolina Ituarte, Natalia Martiarena, Alicia Campanera, Martín Bárcena, Melisa Paolino
{"title":"[Effect of COVID-19 pandemics in treatment of cervical cancer: pre/post study].","authors":"Silvina Arrossi, Fernando Binder, Carolina Ituarte, Natalia Martiarena, Alicia Campanera, Martín Bárcena, Melisa Paolino","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Little evidence exists on the impact of the COVID-19 pandemics on the compliance with cervical cancer treatment.</p><p><strong>Methods: </strong>We carried out a population-based, before-and-after retrospective cohort study of all cervical cancer patients diagnosed in the Jujuy province public health sector (n=140), Argentina, between 2017 and 2020. Patients diagnosed in 2020 were considered exposed to the COVID-19 pandemic (n=21). We used multivariable logistic regression to assess the relationship between the pandemics and compliance with treatment. We also measured treatment duration for women who were indicated brachytherapy and time to treatment initiation by stage.</p><p><strong>Results: </strong>Compared with women diagnosed in 2017-2019 the odds ratio of non-complying with treatment was 1.77 (95%CI 0.59-5.81; p = 0.32) for women diagnosed during 2020. An increased risk of non-compliance was found in patients with prescribed brachytherapy (OR 4.14. 95%CI 1.95-9.11; p < 0.001). Median treatment duration for women with prescribed brachytherapy was 12.8 and 15.7 weeks in 2017-2019 vs. 2020 (p = 0.33); median time to treatment initiation for women with early-stage disease was 9 and 5 weeks during 2017-2019 and 2020 respectively (p = 0.06), vs 7.2 and 9 weeks in 2017-2019 and 2020 respectively (p = 0.36) for patients with stages IIB+ disease.</p><p><strong>Conclusions: </strong>Low access to brachytherapy was a major determinant of non-compliance. irrespective of the effect of the pandemics.</p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"3","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Little evidence exists on the impact of the COVID-19 pandemics on the compliance with cervical cancer treatment.

Methods: We carried out a population-based, before-and-after retrospective cohort study of all cervical cancer patients diagnosed in the Jujuy province public health sector (n=140), Argentina, between 2017 and 2020. Patients diagnosed in 2020 were considered exposed to the COVID-19 pandemic (n=21). We used multivariable logistic regression to assess the relationship between the pandemics and compliance with treatment. We also measured treatment duration for women who were indicated brachytherapy and time to treatment initiation by stage.

Results: Compared with women diagnosed in 2017-2019 the odds ratio of non-complying with treatment was 1.77 (95%CI 0.59-5.81; p = 0.32) for women diagnosed during 2020. An increased risk of non-compliance was found in patients with prescribed brachytherapy (OR 4.14. 95%CI 1.95-9.11; p < 0.001). Median treatment duration for women with prescribed brachytherapy was 12.8 and 15.7 weeks in 2017-2019 vs. 2020 (p = 0.33); median time to treatment initiation for women with early-stage disease was 9 and 5 weeks during 2017-2019 and 2020 respectively (p = 0.06), vs 7.2 and 9 weeks in 2017-2019 and 2020 respectively (p = 0.36) for patients with stages IIB+ disease.

Conclusions: Low access to brachytherapy was a major determinant of non-compliance. irrespective of the effect of the pandemics.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
[COVID-19大流行对宫颈癌治疗的影响:前后研究]。
简介:关于 COVID-19 大流行对宫颈癌治疗依从性影响的证据很少:关于 COVID-19 大流行对宫颈癌治疗依从性的影响,几乎没有任何证据:我们对阿根廷胡胡伊省公共卫生部门在 2017 年至 2020 年间诊断的所有宫颈癌患者(n=140)进行了一项基于人群的前后回顾性队列研究。2020年确诊的患者被视为暴露于COVID-19大流行(n=21)。我们使用多变量逻辑回归来评估大流行与治疗依从性之间的关系。我们还测量了有近距离放射治疗指征的妇女的治疗持续时间以及按阶段开始治疗的时间:与2017-2019年确诊的女性相比,2020年确诊的女性不遵守治疗的几率比为1.77(95%CI 0.59-5.81;p = 0.32)。开具近距离放射治疗处方的患者不遵守治疗的风险增加(OR 4.14. 95%CI 1.95-9.11; p < 0.001)。2017-2019年与2020年,开具近距离治疗处方的妇女的中位治疗时间分别为12.8周和15.7周(p = 0.33);2017-2019年与2020年,早期疾病妇女的中位治疗开始时间分别为9周和5周(p = 0.06),2017-2019年与2020年,IIB+期疾病患者的中位治疗开始时间分别为7.2周和9周(p = 0.36):无论大流行病的影响如何,近距离放射治疗的可及性低是导致不依从的主要决定因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1